Satsuma Pharma's STS101 flunks late-stage migraine study, shares down 84%

Satsuma Pharma's STS101 flunks late-stage migraine study, shares down 84%

Submitted by admin on September 10, 2020 - 10:23am
Source: 
Seeking Alpha
News Tags: 
migraines
Satsuma Pharmaceuticals
clinical trials
STS101
Headline: 
Satsuma Pharma's STS101 flunks late-stage migraine study, shares down 84%
snippet: 

Thinly traded micro cap Satsuma Pharmaceuticals (NASDAQ:STSA) tanks 84% premarket on robust volume in reaction to an unsuccessful Phase 3 EMERGE efficacy trial evaluating STS101 (dihydroergotamine) (DHE) as an acute treatment for migraine.

Do Not Allow Advertisers to Use My Personal information